Next Generation AAV Vectors
Inspired By Nature – Motivated by Health
At rAAVen Therapeutics, we combine rigorous science with curiosity-driven research to enable the next generation of gene therapies. Leveraging deep expertise in AAV biology, we design and engineer novel capsids to address a wide range of disorders across diverse tissues and organs. Using state-of-the-art methodologies in molecular cloning, high-throughput AAV variant production, and next-generation sequencing, we create viral vectors optimized for precision delivery to defined cell populations and tailored functional properties.
NEWS
rAAVen Therapeutics had the pleasure of taking part in the Meet & Match - Neuroscience Edition event organized by SmiLe Venture Hub.
A great day of conversations, new connections, and shared ideas with people who are just as passionate about building the future of life science as we are.
A special thank you to our CSO, Patrick Aldrin-Kirk, who presented on behalf of rAAVen Therapeutics and sparked some great conversations about our ongoing projects.
June 02, 2026
CONTACT
We welcome inquiries from biotech and pharma teams interested in AAV capsid engineering, platform capabilities, or potential collaborations. Whether you are exploring a specific indication or want to understand how our rAAptr platform can support your gene therapy pipeline, we’re happy to discuss ideas at any stage. Reach out via email at info@raaven.se or through LinkedIn, and a member of the rAAVen team will get back to you.